Comparison 6. RISPERIDONE versus SERTINDOLE - all data short term.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Global state - 1a. No clinically significant response (as defined by the original studies)	1	187	Risk Ratio (M-H, Random, 95% CI)	1.14 [0.92, 1.40]
2 Global state - 1b. No clinically important change (as defined by the original studies)	1	187	Risk Ratio (M-H, Random, 95% CI)	1.24 [0.91, 1.68]
3 Leaving the study early	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
3.1 due to any reason	2	508	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.63, 1.06]
3.2 due to adverse events	2	508	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.39, 1.35]
3.3 due to inefficacy	2	508	Risk Ratio (M-H, Random, 95% CI)	0.76 [0.46, 1.25]
4 Mental state: 1a. General - no clinically important change (less than 50% PANSS total score reduction)	1	187	Risk Ratio (M-H, Random, 95% CI)	1.14 [0.92, 1.40]
5 Mental state: 1b. General - average endpoint score (PANSS total, high = poor)	2	493	Mean Difference (IV, Random, 95% CI)	−1.98 [−12.20, 8.24]
6 Mental state: 2. Positive symptoms - average endpoint score (PANSS positive, high = poor)	1	172	Mean Difference (IV, Random, 95% CI)	0.80 [−1.35, 2.95]
7 Mental state: 3. Negative symptoms - average endpoint score (PANSS negative, high = poor)	1	172	Mean Difference (IV, Random, 95% CI)	1.30 [−0.53, 3.13]
8 General functioning: General - average endpoint score - (GAF total, high = poor)	1	114	Mean Difference (IV, Random, 95% CI)	2.90 [−2.61, 8.41]
9 Adverse effects: 1. General - at least one adverse effect	2	508	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.90, 1.05]
10 Adverse effects: 2. Death - suicide	1	187	Risk Ratio (M-H, Random, 95% CI)	3.3 [0.14, 79.98]
11 Adverse effects: 3a. Cardiac effects - QTc prolongation	2	508	Risk Ratio (M-H, Random, 95% CI)	0.21 [0.08, 0.51]
12 Adverse effects: 3b. Cardiac effects - QTc abnormalities - change from baseline in ms	2	495	Mean Difference (IV, Random, 95% CI)	−18.60 [−22.37, −14. 83]
13 Adverse effects: 4. Central nervous system - sedation	2	508	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.69, 1.92]
14 Adverse effects: 5a. Extrapyramidal effects	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
14.1 akathisia	1	321	Risk Ratio (M-H, Random, 95% CI)	2.24 [1.02, 4.92]
14.2 extrapyramidal symptoms	1	187	Risk Ratio (M-H, Random, 95% CI)	1.53 [0.90, 2.61]
14.3 parkinsonism	1	321	Risk Ratio (M-H, Random, 95% CI)	4.11 [1.44, 11.73]
14.4 tremor	1	187	Risk Ratio (M-H, Random, 95% CI)	0.66 [0.16, 2.69]
15 Adverse effects: 5b. Extrapyramidal symptom scales	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
15.1 abnormal involuntary movement: AIMS (high = poor)	2	477	Mean Difference (IV, Random, 95% CI)	0.31 [−0.25, 0.86]
15.2 akathisia: Barnes Akathisia Scale (high = poor)	2	500	Mean Difference (IV, Random, 95% CI)	0.22 [0.03, 0.41]
15.3 extrapyramidal symptoms: Simpson-Angus Scale (high = poor)	2	500	Mean Difference (IV, Random, 95% CI)	0.37 [−0.61, 1.35]
16 Adverse effects: 6. Prolactin associated side effects - sexual dysfunction	2	437	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.16, 0.76]
16.1 abnormal ejaculation	1	250	Risk Ratio (M-H, Random, 95% CI)	0.41 [0.16, 1.03]
16.2 sexual dysfunction	1	187	Risk Ratio (M-H, Random, 95% CI)	0.22 [0.05, 0.98]
17 Adverse effects: 7a. Metabolic - cholesterol - change from baseline in mg/dl	1	176	Mean Difference (IV, Random, 95% CI)	4.90 [−3.73, 13.53]
18 Adverse effects: 7b. Metabolic - glucose - change from baseline in mg/dl	1	176	Mean Difference (IV, Random, 95% CI)	2.00 [−5.85, 9.85]
19 Adverse effects: 7c. Metabolic - weight gain	1	187	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.41, 1.43]
20 Adverse effects: 7d. Metabolic - weight gain - change from baseline in kg	2	328	Mean Difference (IV, Random, 95% CI)	−0.99 [−1.86, −0.12]